ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

Genentech’s Ferrara Selected for GM Award.

June 23, 2006

Kyprolis Demonstrates Overall Response Following FDA Accelerated Approval

August 31, 2012

In Brief: Fisher, Moore, Metcalf to Share Hammer Prize; NCAB Hearing On Organ Systems Program Dec. 3

October 30, 1987

Study: Routine CT Not Needed In Detecting DLBCL Remissions

May 31, 2013

DRCCA Committee, ACCC, DeVita Reach Agreement On CCOP

October 16, 1981

Las Vegas Cancer Center Cuts Staff, Seeks Lifelines During “Perfect Storm”

May 20, 2011